Executive Overview
In a significant development for the global oncology landscape, pharmaceutical giants MSD (known as Merck & Co. in the United States and Canada) and Gilead Sciences have jointly announced the termination of the Phase III KEYNOTE-D46/EVOKE-03 clinical trial (NCT05609968). The pivotal study was designed to evaluate a high-profile, dual-therapy regimen combining Gilead’s antibody-drug conjugate (ADC), Trodelvy (sacituzumab govitecan), with MSD’s blockbuster immuno-oncology cornerstone, Keytruda (pembrolizumab), as a first-line treatment for metastatic non-small cell lung cancer (NSCLC) patients expressing programmed death-ligand 1 (PD-L1).
The decision to discontinue the trial comes on the heels of a formal recommendation issued by an independent external data monitoring committee (DMC). During a scheduled interim review, the committee projected that the combined therapy approach would fail to demonstrate a statistically significant improvement in overall survival (OS)—the study’s primary endpoint—when compared against the current standard of care involving Keytruda monotherapy.
While the trial did reveal a numerical, additive benefit in progression-free survival (PFS), this trend fell short of statistical significance, rendering the primary clinical objective unachievable under pre-specified regulatory and scientific parameters. Notably, the safety profile of the combination remained consistent with the established individual safety frameworks of both agents, with no new or unexpected adverse safety signals reported during the course of the trial.
This discontinuation serves as a tactical blow to Gilead’s aggressive commercial expansion strategy for Trodelvy, a drug central to the company’s long-term oncology revenue diversification. Trodelvy, an ADC directed against TROP2, represents a cornerstone of Gilead’s multi-billion-dollar bet on next-generation targeted cancer therapies. For MSD, the setback marks a minor detour in an otherwise expansive life-cycle management program for Keytruda, a drug facing a looming patent cliff in 2028. Despite this setback, both pharmaceutical powerhouses remain committed to their respective pipeline development pathways, pivoting swiftly toward alternative indications, monotherapy pathways, and emerging alternative assets designed to redefine the boundaries of modern cancer care.
Detailed Chronology of the KEYNOTE-D46/EVOKE-03 Trial
The journey of the KEYNOTE-D46/EVOKE-03 trial highlights the immense scientific rigor, regulatory hurdles, and inherent clinical uncertainties governing contemporary cancer drug development.
Initiation and Trial Design
The Phase III KEYNOTE-D46/EVOKE-03 study was formally registered and launched to investigate whether the vertical integration of two mechanisms of action—targeted chemotherapy delivery via Trodelvy’s payload combined with immune checkpoint inhibition via Keytruda—could overcome the therapeutic resistance frequently observed in frontline non-small cell lung cancer.
The trial enrolled patients with previously untreated, locally advanced or metastatic NSCLC whose tumors expressed PD-L1. The experimental arm received the concurrent administration of Trodelvy and Keytruda, while the control arm received Keytruda monotherapy, which remains a primary global standard of care for this patient population. The dual-primary endpoints were designed to rigorously assess progression-free survival (PFS) and overall survival (OS) across the randomized patient cohorts.
The Interim Analysis and DMC Verdict
As standard practice in late-stage oncology trials, an external data monitoring committee—an independent panel of clinical and statistical experts—was tasked with reviewing unblinded efficacy and safety data at pre-specified interim milestones. During this comprehensive evaluation, the committee analyzed mature survival data trends to project the final trajectory of the trial.
The statistical modeling indicated that the combination therapy was unlikely to achieve the targeted threshold for overall survival superiority over the Keytruda-alone arm. Although patients receiving the Trodelvy-Keytruda combination experienced a modest, numerical improvement in progression-free survival, the magnitude of this effect did not clear the hurdle of statistical significance required to support regulatory submissions for a new first-line standard of care. Consequently, the DMC recommended the discontinuation of the trial to protect patient resources and allow investigators to redirect efforts toward more promising avenues of clinical research.
Immediate Aftermath and Wind-Down Procedures
Following the DMC’s recommendation, Gilead and MSD acted in unison to formally terminate the study. Protocol-defined wind-down procedures were initiated immediately, ensuring that patients currently enrolled in the trial are transitioned safely to alternative post-trial care regimens determined by their primary treating oncologists. Investigators across global trial sites were notified, and clinical operations related to patient accrual and follow-up under KEYNOTE-D46/EVOKE-03 were brought to an orderly close.
Supporting Context, Pipeline Implications, and Market Metrics
The discontinuation of the NSCLC trial reverberates across both corporate portfolios, altering near-term commercial forecasts and refocusing research and development priorities.
Gilead’s Trodelvy Strategy: Navigating Setbacks and Doubling Down
For California-based Gilead Sciences, Trodelvy represents a critical engine of future growth. Acquired via the multi-billion-dollar buyout of Immunomedics, Trodelvy has steadily expanded its footprint in solid tumors. US regulators have previously granted approvals for Trodelvy in patients with pre-treated metastatic triple-negative breast cancer (TNBC) and certain lines of pre-treated hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer, as well as pre-treated metastatic urothelial cancer.
Financially, Trodelvy continues to demonstrate robust commercial momentum. During the second quarter of 2026, the drug reported worldwide sales growth of 26% year-on-year, generating approximately $457 million for the quarter. Despite this strong financial performance, expanding the drug into lucrative frontline settings—such as non-small cell lung cancer—is essential for Gilead to achieve blockbuster status on a scale comparable to established immunotherapy giants.
Gilead management has emphasized that the failure of KEYNOTE-D46/EVOKE-03 does not compromise the broader matrix of ongoing clinical trials investigating Trodelvy both as a monotherapy and in alternate combination strategies. The company continues to evaluate the ADC in several high-stakes programs, including:
- ASCENT-05 Trial (NCT05633654): A critical Phase III study testing Trodelvy combined with Keytruda against physician’s choice therapy in patients with high-risk, adjuvant triple-negative breast cancer (TNBC). This trial remains the primary focus for the immediate realization of the Trodelvy-Keytruda clinical synergy hypothesis.
- Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Late-stage monotherapy trials investigating Trodelvy’s efficacy in managing aggressive neuroendocrine lung tumors.
- Metastatic Endometrial Cancer: Ongoing evaluations positioned in the second-line and later settings to capture unmet needs in gynecological oncology.
MSD and the Keytruda Life-Cycle Management Strategy
For MSD, Keytruda (pembrolizumab) stands as one of the most successful pharmaceutical products in medical history. Having secured regulatory approvals across more than 20 distinct cancer types, Keytruda has fundamentally reshaped the oncology treatment paradigm. However, the drug’s commercial supremacy faces an immutable expiration date: MSD anticipates that Keytruda will lose its core market exclusivity in 2028, setting the stage for a massive generic and biosimilar patent cliff.
To mitigate the impending revenue contraction, MSD has executed an aggressive life-cycle management and pipeline fortification strategy. A cornerstone of this strategy involves identifying next-generation ADCs and combination partners that can seamlessly transition into the therapeutic space currently dominated by Keytruda.
Of particular note is MSD’s partnership surrounding sacituzumab tirumotecan (sac-TMT), a TROP2-targeting ADC developed by Kelun Biotech. Sac-TMT has already achieved notable Phase III successes in late-stage NSCLC and endometrial cancer trials. Current market analyses from GlobalData project that sac-TMT is well-positioned to achieve blockbuster status by 2029, effectively serving as an internal successor and evolutionary step in MSD’s oncology portfolio as Keytruda approaches its patent expiration.
Official Statements and Industry Perspectives
Corporate leadership from both Gilead Sciences and MSD have maintained a pragmatic and forward-looking posture in the wake of the KEYNOTE-D46/EVOKE-03 outcome.
In communications addressing institutional investors and the clinical community, representatives from Gilead reaffirmed their commitment to rigorous scientific inquiry in the field of antibody-drug conjugates. Executives underscored that clinical development in oncology inherently involves navigating complex biological pathways where combinatorial synergy cannot always be guaranteed, even when individual agents possess proven clinical activity. Gilead noted that the safety data gathered throughout the trial reaffirm Trodelvy’s manageable tolerability profile, providing a safe foundation for ongoing trials in breast and lung malignancies.
MSD echoed these sentiments, emphasizing that strategic collaborations remain vital to pushing the boundaries of cancer therapeutics. Company spokespersons highlighted that while the frontline NSCLC indication with Trodelvy did not yield the desired survival benefit, MSD’s sprawling oncology pipeline—anchored by diverse immunotherapy combinations and next-generation ADCs such as sac-TMT—remains robust and fully capable of sustaining the company’s long-term leadership in cancer care.
Independent clinical oncologists and oncology analysts have also weighed in on the trial’s termination. Many experts pointed out that lung cancer remains one of the most genetically heterogeneous and biologically resilient tumor microenvironments. The failure of the Trodelvy-Keytruda combination underscores the reality that simply pairing an effective ADC with an immune checkpoint inhibitor does not guarantee synergistic clinical outcomes across all patient subgroups, particularly in frontline settings where tumor heterogeneity and compensatory survival pathways can blunt therapeutic impact.
Future Outlook: The Road Ahead for TROP2 ADCs and Oncology Combinations
The termination of the KEYNOTE-D46/EVOKE-03 study marks the conclusion of one chapter in the clinical exploration of TROP2-directed antibody-drug conjugates, but it simultaneously catalyzes new avenues of research across the pharmaceutical sector.
Refining Biomarker Selection and Patient Stratification
A major takeaway for clinical trial designers moving forward is the absolute necessity of refined patient stratification and biomarker discovery. As the oncology field transitions further into personalized medicine, broad-stroke combination trials involving unselected or broadly defined populations (such as all PD-L1-expressing NSCLC patients) carry higher risks of neutral or negative outcomes. Future protocols are expected to incorporate more granular molecular profiling, examining specific genomic co-mutations, TROP2 expression density, and immune microenvironment signatures to pinpoint the exact patient cohorts most likely to derive true benefit from complex ADC-immunotherapy regimens.
The Evolving TROP2 ADC Landscape
The competitive arena surrounding TROP2-targeting ADCs remains intensely active. With multiple pharmaceutical players advancing distinct ADC constructs featuring varying antibody frameworks, linker technologies, and payloads (such as topoisomerase I inhibitors), the race to optimize clinical efficacy continues unabated. Data readouts from trials such as Gilead’s ASCENT-05 in adjuvant TNBC will be closely monitored by the global medical community to determine whether the Trodelvy-Keytruda pairing can successfully secure a regulatory foothold in other disease settings.
Simultaneously, the maturation of alternative TROP2 assets, such as MSD’s partnered sac-TMT portfolio, indicates that the therapeutic class as a whole remains a high-conviction target for the pharmaceutical industry. The lessons learned from the KEYNOTE-D46/EVOKE-03 trial will undoubtedly inform the design, dosing strategies, and patient selection criteria for these incoming pipeline assets.
Conclusion
Ultimately, while the discontinuation of the Phase III KEYNOTE-D46/EVOKE-03 trial represents a disappointing outcome for Gilead Sciences and MSD, it exemplifies the self-correcting nature of rigorous clinical research. By identifying the limitations of the Trodelvy-Keytruda combination in frontline NSCLC early through independent data monitoring, both companies have preserved vital resources to channel into higher-probability clinical programs. As Gilead advances its monotherapy and combination trials in breast and lung cancers, and as MSD fortifies its pipeline ahead of the 2028 Keytruda patent cliff, the oncology community continues its relentless pursuit of more effective, durable, and personalized treatment paradigms for cancer patients worldwide.